Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. RESULTS: Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33% [3.6 mmol/mol]; 1.2 mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01). CONCLUSIONS: In a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a potential risk of severe hypoglycemia if persons with DM do not appropriately reduce the prandial insulin dosage.1171–1174”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“The amylin analog pramlintide, the only other medication approved for the treatment of T1D, is administered with prandial insulin.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“A1C reductions are consistently modest, and mild weight loss is common.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Tachyphylaxis is often seen after several years of therapy.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Nausea is a common adverse effect.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 4×
“At 26 weeks, significantly more subjects receiving liraglutide 1.8 mg compared with placebo achieved the ADA target of HbA1c,7.0% (,53.0mmol/mol) (18.8 vs. 10.0%, respectively, odds ratio [OR] 2.12 [95% CI 1.11; 4.06], P = 0.0231) (Fig.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E. H. M., Wolffenbuttel, B. H. R., & Niessen, L. W. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.458 · Cited by 565
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Furthermore, liraglutide decreases food intake (9) and has weight loss benefits in type 2 diabetes (10–14).”
BackgroundBradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Research works printed but not linked: 3
- FDA, 2005, New diabetes drug, FDA Consum, 39, 3
- 2013, Kidney Disease: Improving Global Outcomes. Definition and classification of CKD, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 3, 19
- Østergaard, 2015, Effects of liraglutide as add-on to insulin on counter-regulatory hormone responses, gastric emptying and glycaemic recovery during hypoglycaemia (Abstract), Diabetologia, 58, A963
Cited by
Items 201–271 of 271
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Borg, D. J., Faridi, P., Giam, K., Reeves, P., Fotheringham, A. K., McCarthy, D. A., Leung, S. S., Ward, M. S., Harcourt, B. E., Ayala, R., et al. (2021) · Metabolites · doi:10.3390/metabo11070426 · Cited by 2
“Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide expression in the gut of NOD mice appear unchanged by hyperglycaemia [40], and although combinatory therapies with GLP-1 receptor agonists in individuals with T1D have the potential to enhance β-cell function [41], recent Phase III trials (NCT01836523,…”
BackgroundPopovic, D. S., Stoian, A. P., & Παπάνας, Ν. (2023) · Endocrine · doi:10.1007/s12020-022-03294-3 · Cited by 2
Alexander, G. C., Xu, Y., Xiao, X., Lewis, S. V., Zeger, S., & Mehta, H. B. (2026) · Obesity · doi:10.1002/oby.70076 · Cited by 1
“For example, in a pivotal trial of liraglutide, the ADJUNCT 2 trial, individuals in the liraglutide group lost between 3.0% and 6.1% (2.5–5.1 kg) of baseline weight at week 26, as compared with 0.2% (0.2 kg) among the placebo group [23].”
InfluentialDeniz, M. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006990 · Cited by 1
Pasqua, M., Doumat, J., Tsoukas, M. A., & Haidar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.10.175 · Cited by 1
Thiyagarajan, S. K., Wall‐Wieler, E., Liu, Y., Zheng, F., & Edwards, M. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08467-3 · Cited by 2
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“60,61 Results demonstrated a dose-dependent weight loss of up to 5.1 kg, and improvements in quality-of-life scores, but the relatively small drop in HbA 1c of 0.33% limited enthusiasm for this treatment.”
InfluentialSaeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
Berry, S. A., Goodman, I. R., McNally, E. H., Elliott, J., & Iqbal, A. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71080 · Cited by 1
“Consequently, the risk-benefit profile was deemed insufficient for regulatory approval [9, 10].”
Wang, Y., He, S., Yang, H., Zhang, J., Yu, L., Xiong, J., Li, X., Qiu, J., & Ma, B. (2026) · Biology · doi:10.3390/biology15171472 · Cited by 1
GLP-1-Analoga auch für Typ-1-Diabetiker?
Stiefelhagen, P. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0997-7 · Cited by 1
Developments in the Management of Type 1 and Type 2 Diabetes
Mathieu, C. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.13 · Cited by 2
“Two large adjunct studies in patients with T1D have shown that adding liraglutide to intensive insulin therapy showed an improved effect on HbA1c with less insulin and with weight reduction.(4,5) However, by 1 year the effect was diminished.”
BackgroundSelf-citationJones, A. G., & McDonald, T. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13290 · Cited by 1
“This is consistent with studies in Type 1 diabetes, where minimal glycaemic response to GLP-1 receptor agonists is seen, except in participants with preserved endogenous insulin secretion.(3) To further clarify the differences in the findings of the two studies, we would like to emphasize additional important differen…”
ResultSNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · doi:10.2337/figshare.29575130 · Cited by 3
Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus
Sabet, S., Condren, M. E., Boston, A., Doak, L. C., & Chalmers, L. J. (2018) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-23.5.351 · Cited by 1
Buse, J. B. (2018) · US Endocrinology · doi:10.17925/use.2018.14.2.54
Self-citationSGLT inhibitors for type 1 diabetes: a finely balanced matter?
Morris, D. (2020) · Independent Nurse · doi:10.12968/indn.2020.4.14 · Cited by 1
Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
Boughton, C. K., & Hovorka, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3654
Doggrell, S. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3702
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Schandl, L., & Winkler, G. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.19
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes
Sehly, A. J. A., Altemani, R. F. H., Alharthi, Y. H. J., Alhwiti, A. G. S., Bedaiwi, A. A. A., Alqulayti, W. M., Alshuwaier, R. A. I., Alaql, A., & Ajwah, I. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/skbdqro7ng
Kombinationstherapien mit Insulin bei Typ-1-Diabetes
Gallwitz, B. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00795-z
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430
Type 1 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch7
Future Role of Non-Insulin Antihyperglycemic Agents in the Management of Type 1 Diabetes Mellitus
Senior, P. A. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1211
Jones, A. G., Shields, B. M., Oram, R. A., Dabelea, D., Hagopian, W., Lustigova, E., SHAH, A. S., Knupp, J., Mottl, A. K., D’Agostino, R. B., et al. (2023) · medRxiv · doi:10.1101/2023.09.27.23296128
“Consistent with this, within individuals with longstanding diabetes assessment of insulin secretion, using c-peptide has been shown to predict successful insulin withdrawal, glucose variability and hypoglycaemia risk, and response to prandial insulin and non-insulin glucose lowering therapies, regardless of clinician…”
BackgroundHeald, A. H., Warner-Levy, J. J., Belston, L., Habte‐Asres, H. H., Horne, L., Metters, A., Whyte, M., & Gibson, M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000293
Tsoukas, M. A. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1318
Cheng, Y., Li, H., Liu, X., Jin, X., Han, J., Du, J., & Xu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1381248
GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review
Furió-Novejarque, C., Díez, J.-L., & Bondía, J. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241285925 · Cited by 3
“8-10 However, its higher risk of hypoglycemia and ketosis 11 has resulted in a lack of approval for T1D by the FDA.”
Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes?
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2024) · Medical Research Archives · doi:10.18103/mra.v12i12.6110
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
Insulin Resistance in Type 1 Diabetes and Its Treatment Strategies
孙, 全. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153617
Stopyra, M., Feret, K., Andrzejczyk, A., Nafalska, N., Tomaszewska, A., Gadzinowska, J., Kokoszka, M., Chodór, M., Szpila, G., & Lewandowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3970
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
Minsky, N. C., Olshanskiy, D., & Aharon‐Hananel, G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70389
“8,9 However, emerging evidence suggests semaglutide may offer superior benefits with acceptable safety in selected individuals with T1D.”
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Pasqua, M.-R. (2025) · eScholarship@McGill (McGill) · doi:10.82308/10658
Treatment of people with type 1 diabetes with Semaglutide or Tirzepatide – Relevant in the future?
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v13i9.6925 · Cited by 1
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Hayek, A. A., Robert, A. A., Alburayk, A. K., Alwadai, A. N., Almutairi, A. M., Shabani, A. A., & Dawish, M. A. A. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998428827251223081042
Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
Mottl, A. K., Sawinski, D. L., & Bjornstad, P. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.022
Metabolic dysfunction and the use of adjunct medications in type 1 diabetes
Luk, A., Cheah, Y. S., Misra, S., & Salem, V. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000956
周, 玮. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641306
GLP-1 receptor agonists and acute diabetes complications in adults with type 1 diabetes
Dai, H., Lee, Y. A., Radwan, R. M., Sheer, A. J., Hannon, T. S., Hayes, M. R., Sun, R. C., Bian, J., & Guo, J. (2026) · iScience · doi:10.1016/j.isci.2026.115700
“20,21 These findings tempered enthusiasm of GLP-1 RA use in T1D despite their marked benefits in improving cardiovascular and renal outcomes.”
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes
Innes, R., Petrie, J. R., & Dejgaard, T. F. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.002
Yazdanfard, P. D. W., Kosjerina, V., Wood-Kurland, H. K., Andersen, M. P., Hommel, E. E., Dejgaard, T. F., Nørgaard, K., Torp-Pedersen, C. T., & Sørensen, K. K. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101716 · Cited by 1
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.007
Ghanim, H., Srungavarapu, S. R., Dandona, P., & Chaudhuri, A. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.009
Lim, C.-E., Pasternak, B., Eliasson, B., Pazzagli, L., & Ueda, P. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101729
Hughes, M. S., & Pasquel, F. J. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.015
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
“13–16 However, as their indications expand, concerns regarding potential adverse effects have also grown.”
Tentolouris, A., Popovic, D. S., Liarakos, A. L., Briasoulis, Α., Παπάνας, Ν., & Koufakis, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71045
Refining metabolic‐response signals after liraglutide therapy in type 1 diabetes
Zheng, J., & Zhang, J. N. (2026) · Diabetic Medicine · doi:10.1111/dme.70417
Alkhushaym, N., Almutairi, W., ALANAZI, S., Balharith, R., Alhifany, A. A., & Musa, I. R. (2026) · Research Square · doi:10.21203/rs.3.rs-10216709/v1
Timmons, J. G., Ghanim, H., Boyle, J. G., Greenlaw, N., Chaudhuri, A., Batra, M., Lindsay, R. S., Jolly, L., Bonner, C., McConnachie, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71076
“…in T1D, as effect sizes for outcomes such as HbA1c, body weight and total daily insulin dose in trials with the daily GLP-1 agonists were smaller than desired and offset by increased rates of adverse effects including hypoglycaemia and ketosis (depending on the insulin dosing schedule) [20, 21].”
Almoallem, B., & Thalange, N. K. S. (2026) · Cureus · doi:10.7759/cureus.114782
Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications
Bloomgarden, Z. T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70427
“ADJUNCT TWO showed similar bene fi ts with capped insulin and again raised hypoglycemia and ketosis concerns 28 , although none of the participants in these studies employed CGM.”
Kitsios, K., & Trakatelli, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261486127
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z · Cited by 1
Self-citationThe Need for an Integrative Approach in Type 1 Diabetes Management
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8457-6
Decoding inflammation to target hybrid diabetes phenotypes
Rossi, G., Terranegra, A., Lunati, M. E., Pastore, I., CANOVA, L. P., Bucciarelli, L. G., Cimino, V., Loretelli, C., Nasr, M. B., Fiorina, P., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922969
GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Rossatto, T., Oliveira, R. D. A., & Cardoso, A. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71428
Araszkiewicz, A., Cyganek, K., Cypryk, K., CYRANKA, K., Czupryniak, L., Dąbrowski, M., Dzida, G. J., Gawrecki, A., Głowińska‐Olszewska, B., Grabski, B., et al. (2026) · Current Topics in Diabetes · doi:10.5114/ctd/226021
Metadata
- Authors
- Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., Buse, J. B., & for the ADJUNCT TWO Investigators
- Affiliations
- Lund University, Lund, Sweden
- University of Washington (US)
- Medical University of Graz (AT)
- KU Leuven (BE)
- Hospital General de Segovia, Segovia, Spain
- Aarhus University Hospital (DK)
- University of Cape Town (ZA)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-04
- Volume
- 39
- Issue
- 10
- Pages
- 1693-1701
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2494601841
- Cited by
- 262
- References
- 36
- Citations by year
- 2026: 38 · 2025: 49 · 2024: 33 · 2023: 25 · 2022: 16 · 2021: 23 · 2020: 29 · 2019: 11 · 2018: 21 · 2017: 10 · 2016: 7
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, GLP-1 receptor agonists, HbA1c, glycemic control, weight loss, insulin dose reduction, hypoglycemia, diabetic ketoacidosis, quality of life
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.